Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
Fort Lee, NJ , June 20, 2023 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT)…
Year: 2023
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy…
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy…
ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer
SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) — ShapeTX, the programmable medicine company using AI and…
ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer
SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) — ShapeTX, the programmable medicine company using AI and…
Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease
–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for…
Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease
–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for…
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions
LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for…
Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions
LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for…
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
– Phase 2 topline interim results expected in 1Q 2024 – – 6-month durability data for…
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
– Phase 2 topline interim results expected in 1Q 2024 – – 6-month durability data for…
Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis
– First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That…
Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis
– First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That…
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Media Release SYDNEY, AUSTRALIA, June 20, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ:…
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Media Release SYDNEY, AUSTRALIA, June 20, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ:…
Spectral Medical Provides Update on Continued Favorable Tigris Clinical Trial Enrollment
Tigris trial enrollment at 64 patients Crude mortality results continue to exceed expectations TORONTO, June…
Spectral Medical Provides Update on Continued Favorable Tigris Clinical Trial Enrollment
Tigris trial enrollment at 64 patients Crude mortality results continue to exceed expectations TORONTO, June…
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance,…
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance,…
Aridis Pharmaceuticals’ AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
LPAD may provide alternative pathways for streamlined product approval LOS GATOS, Calif., June 20, 2023…